GW Pharma had a US$3 billion market cap prior to one dollar of revenue from epidiolex. I agree the value will come from the IP.
Any revenue in the next couple of years would be a small cherry on top of the value created by the clinical programs. And importantly the company now has a bullet proof balance sheet to execute, regardless of what global markets do.
IHL Price at posting:
21.0¢ Sentiment: Buy Disclosure: Held